These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 9331500)
1. Bone marrow mononuclear cell count does not predict neutrophil and platelet recovery following autologous bone marrow transplant: value of the colony-forming unit granulocyte-macrophage (CFU-GM) assay. al-Fiar F; Prince HM; Imrie K; Stewart AK; Crump M; Keating A Cell Transplant; 1997; 6(5):491-5. PubMed ID: 9331500 [TBL] [Abstract][Full Text] [Related]
2. Recovery of CFU-GM from cryopreserved marrow and in vivo evaluation after autologous bone marrow transplantation are predictive of engraftment. Douay L; Gorin NC; Mary JY; Lemarie E; Lopez M; Najman A; Stachowiak J; Giarratana MC; Baillou C; Salmon C Exp Hematol; 1986 Jun; 14(5):358-65. PubMed ID: 3519263 [TBL] [Abstract][Full Text] [Related]
3. A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation. Smith RJ; Sweetenham JW Exp Hematol; 1995 Dec; 23(14):1581-8. PubMed ID: 8542950 [TBL] [Abstract][Full Text] [Related]
4. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Pettengell R; Morgenstern GR; Woll PJ; Chang J; Rowlands M; Young R; Radford JA; Scarffe JH; Testa NG; Crowther D Blood; 1993 Dec; 82(12):3770-7. PubMed ID: 7505124 [TBL] [Abstract][Full Text] [Related]
5. Analysis for recovery and loss of mononuclear cells and colony-forming units granulocyte-macrophage during ex vivo processing of autologous bone marrow. Schwella N; Heuft HG; Rick O; Blasczyk R; Wittmann G; Huhn D Vox Sang; 1996; 70(3):132-8. PubMed ID: 8740003 [TBL] [Abstract][Full Text] [Related]
6. Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow. Carlo-Stella C; Mangoni L; Almici C; Cottafavi L; Meloni G; Mandelli F; Rizzoli V Blood; 1992 Nov; 80(9):2412-8. PubMed ID: 1421413 [TBL] [Abstract][Full Text] [Related]
7. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation. Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941 [TBL] [Abstract][Full Text] [Related]
8. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Dreger P; Klöss M; Petersen B; Haferlach T; Löffler H; Loeffler M; Schmitz N Blood; 1995 Nov; 86(10):3970-8. PubMed ID: 7579368 [TBL] [Abstract][Full Text] [Related]
9. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation. Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338 [TBL] [Abstract][Full Text] [Related]
10. GM-CSF therapy for delayed engraftment after autologous bone marrow transplantation. Brandwein JM; Nayar R; Baker MA; Sutton DM; Scott JG; Sutcliffe SB; Keating A Exp Hematol; 1991 Mar; 19(3):191-5. PubMed ID: 1995310 [TBL] [Abstract][Full Text] [Related]
11. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience. Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585 [TBL] [Abstract][Full Text] [Related]
12. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial. Vose JM; Pandite AN; Beveridge RA; Geller RB; Schuster MW; Anderson JE; LeMaistre CF; Ahmed T; Granena A; Keating A; Fernandez Ranada JM; Stiff PJ; Tabbara I; Longo W; Copelan EA; Nichols C; Smith A; Topolsky DL; Bierman PJ; Lebsack ME; Lange M; Garrison L J Clin Oncol; 1997 Apr; 15(4):1617-23. PubMed ID: 9193361 [TBL] [Abstract][Full Text] [Related]
13. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for relapsed non-Hodgkin's lymphoma: blood and bone marrow progenitor growth studies. A phase II Eastern Cooperative Oncology Group Trial. Lazarus HM; Andersen J; Chen MG; Variakojis D; Mansour EG; Oette D; Arce CA; Oken MM; Gerson SL Blood; 1991 Aug; 78(3):830-7. PubMed ID: 1859894 [TBL] [Abstract][Full Text] [Related]
14. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma. Lemoli RM; Rosti G; Visani G; Gherlinzoni F; Miggiano MC; Fortuna A; Zinzani P; Tura S J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500 [TBL] [Abstract][Full Text] [Related]
15. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Demuynck HM; Link H; Zander A; Barge A Lancet; 1996 Feb; 347(8998):353-7. PubMed ID: 8598700 [TBL] [Abstract][Full Text] [Related]
16. Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial. Gorin NC; Coiffier B; Hayat M; Fouillard L; Kuentz M; Flesch M; Colombat P; Boivin P; Slavin S; Philip T Blood; 1992 Sep; 80(5):1149-57. PubMed ID: 1515637 [TBL] [Abstract][Full Text] [Related]
17. Relationship of infused CFU-GM and CFU-Mk mobilized by chemotherapy with or without G-CSF to platelet recovery after autologous blood stem cell transplantation. Takamatsu Y; Harada M; Teshima T; Makino S; Inaba S; Akashi K; Shibuya T; Niho Y Exp Hematol; 1995 Jan; 23(1):8-13. PubMed ID: 7527786 [TBL] [Abstract][Full Text] [Related]
18. GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease. Devereaux S; Linch DC; Gribben JG; McMillan A; Patterson K; Goldstone AH Bone Marrow Transplant; 1989 Jan; 4(1):49-54. PubMed ID: 2647187 [TBL] [Abstract][Full Text] [Related]
19. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment. Bolwell BJ; Fishleder A; Andresen SW; Lichtin AE; Koo A; Yanssens T; Burwell R; Baucco P; Green R Bone Marrow Transplant; 1993 Dec; 12(6):609-14. PubMed ID: 7511016 [TBL] [Abstract][Full Text] [Related]